Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2021-09-04T10:16:22Z | - |
dc.date.available | 2021-09-04T10:16:22Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91821 | - |
dc.description.abstract | This study aimed to assess the relative efficacy and safety of tofacitinib 5 and 10 mg twice daily, or in combination with methotrexate (MTX), in patients with active RA. Randomized controlled trials (RCTs) examining the efficacy and safety of tofacitinib in patients with active RA were included in this network meta-analysis. We performed a Bayesian network meta-analysis to combine the direct and indirect evidence from the RCTs. Ten RCTs including 4867 patients met the inclusion criteria. There were 21 pairwise comparisons including 11 direct comparisons of seven interventions. The ACR20 response rate was significantly higher in the tofacitinib 10 mg + MTX group than in the placebo and MTX groups (OR 7.56, 95 % credible interval (CrI) 3.07-21.16; OR 3.67, 95 % CrI 2.60-5.71, respectively). Ranking probabilities based on the surface under the cumulative ranking curve (SUCRA) indicated that tofacitinib 10 mg + MTX had the highest probability of being the best treatment for achieving the ACR20 response rate (SUCRA = 0.9254), followed by tofacitinib 5 mg + MTX (SUCRA = 0.7156), adalimumab 40 mg + MTX (SUCRA = 0.6097), tofacitinib 10 mg (SUCRA = 0.5984), tofacitinib 5 mg (SUCRA = 0.4749), MTX (SUCRA = 0.1674), and placebo (SUCRA = 0.0086). In contrast, the safety based on the number of withdrawals due to adverse events did not differ significantly among the seven interventions. Tofacitinib, at dosages 5 and 10 mg twice daily, in combination with MTX, was the most efficacious intervention for active RA and was not associated with a significant risk for withdrawals due to adverse events. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject | INADEQUATE RESPONSE | - |
dc.subject | JAK INHIBITOR | - |
dc.subject | CP-690,550 | - |
dc.subject | PLACEBO | - |
dc.subject | DISEASE | - |
dc.subject | COMBINATION | - |
dc.subject | INCONSISTENCY | - |
dc.subject | MONOTHERAPY | - |
dc.subject | ADALIMUMAB | - |
dc.title | Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.1007/s00296-015-3291-4 | - |
dc.identifier.scopusid | 2-s2.0-84947616388 | - |
dc.identifier.wosid | 000365291100003 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY INTERNATIONAL, v.35, no.12, pp.1965 - 1974 | - |
dc.relation.isPartOf | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.title | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.volume | 35 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1965 | - |
dc.citation.endPage | 1974 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | JAK INHIBITOR | - |
dc.subject.keywordPlus | CP-690,550 | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | INCONSISTENCY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordAuthor | Tofacitinib | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.